Simbec-Orion is honoured to have been trusted by Oxford Cannabinoid Technologies to run this milestone first-in-human Phase1 clinical trial of its lead compound, OCT461201 for Postherpetic Neuralgia (PHN) & Irritable Bowel Syndrome.
Chief Scientific Officer, Valentino Parravicini recently discussed the significance of partnering with Simbec-Orion for the first-in-human Phase 1 clinical trial of the lead compound, OCT46120. During the interview, he shares the process his team undertook for the selection of their clinical partner, and what drove their final decision.